glp-1 and vision changes Loss MDL Grows 70% Ahead of September Hearings Vision loss: GLP-1 drugs like
Description
Amplifying the efforts of primary care providers (PCPs) in the time between visits with a comprehensive behavior change-backed program
The CV outcome trials (CVOT) (Figure 1) of all the GLP-1 RAs (liraglutide, semaglutide, dulaglutide, albiglutide, extended-release exenatide, and lixisenatide) (Table 1)
They also act on appetite centres in the brain, reducing hunger and food intake
2022;24(1):p
This translated to an 8% lower risk for death due to any cause for those treated with GLP-1 medications (HR = 0.92
